NEW YORK ( TheStreet) -- Idexx Laboratories (Nasdaq: IDXX) hit a new 52-week high Friday as it traded at $76.54 compared with its previous 52-Week high of $75.77. Idexx is changing hands at $76.52 with 64,833 shares traded as of 3:06 p.m. ET. Average volume has been 242,800 shares over the past 30 days. Idexx has a market cap of $4.3 billion and is part of the health care sector and drugs industry. Shares are up 9.1% year to date as of the close of trading on Thursday. IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the veterinary and production animal markets, as well as for the water testing and dairy markets. The company has a P/E ratio of 31.7, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 23.5. TheStreet Ratings rates Idexx as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, notable return on equity, solid stock price performance and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full Idexx Ratings Report.
More from Markets
Teva Shares Higher After Drugmaker Proposes $23B Global Opioid Settlement
The settlement, over and above an earlier agreement to settle with two Ohio counties, aims to resolve all outstanding opioid-related claims.
Stocks End Higher on Renewed Hope for U.S.-China Trade Pact, Earnings Optimism
Stocks finished higher Monday, bolstered by potential progress in the U.S.-China trade war and optimism about upcoming earnings reports.
Market Wrap: Muted Response to Trade Progress, Goldman Sachs Note on Buybacks
S&P 500 buybacks were down 18% in the second quarter according to a Goldman Sachs note.
How Investors Should Approach Positive Headlines Around U.S.-China Trade War
We're finally getting positive headlines around the U.S.-China trade war. Is it too soon to start celebrating?